Gastrointestinal Oncologist at @DanaFarber and @Harvardmed. Aspiring runner. @EinsteinMed, @RutgersU, and @StBenedictsNJ grad.
Boston, MA
Joined March 2019
- Tweets631
- Following948
- Followers1.7K
- Likes2.7K
Just read this 2018 paper and it made me rethink chromosomal instability (CIN) and metastatic disease.
nature.com/articles/nature25…
James Cleary retweeted
Children taking Novartis’s Zolgensma gene therapy for the deadly condition of spinal muscular atrophy have developed tumors, with two confirmed as linked to the treatment bloomberg.com/news/articles/…
James Cleary retweeted
Our atlas of young-onset CRC is finally out in @NatureMedicine! We found a unique biology in younger patients that may explain the aggressive nature of this disease. This was a monumental effort with colleagues at @MassGenBrigham and @broadinstitute. @DFarberYoungCRC
Researchers co-led by @KimmieNgMD of @DanaFarber and @DFarberYoungCRC created the largest single-cell atlas of colorectal cancer ever, identifying age-associated differences that may help research into why #colorectalcancer can be more aggressive in younger adults. ➡️bit.ly/4kmBFEl
James Cleary retweeted
Voting for the ASCO Election is now open.
I am honored to be running as one of the
candidates for the Designated Surgical
Oncologist Seat. Visit asco.org/election to
learn more about the candidates and vote!
James Cleary retweeted
#LBA82 subgroup analysis RASolute 302 #PDAC
➡️HR for OS across subtypes 0.32-0.46
➡️G12R 0.61 (0.29-1.30)
➡️RAS WT numbers small (3%) but still OS benefit!
🤔perhaps ORR and mPFS not as pronounced in these populations!
✅std second line treatment
@myESMO #ESMO26 @OncoAlert
James Cleary retweeted
Every company developing G12X drugs should pay attention to this data at #ESMO26
Zecdarasib (G12Di) plus chemo in 1L metastatic PDAC, phase 1
ORR 89% with mFOLFIRINOX (n=27)
ORR 69% with gem/nab-paclitaxel (n=26)
Awesome safety for early DE.
For context, other early 1L PDAC response rates (cross-trial which we would neeeeever do):
Zoldonrasib + FOLFIRINOX: 82%
Zoldonrasib + gem/nab-P: 61%
Daraxonrasib + gem/nab-P: 59%
Daraxonrasib alone: 47%
Chemo clearly still matters. Starting to think about this like Breakwater…
In PDAC, monoallelic inhibitors are extremely effective, just more effective with a little extra oomph behind them.
They will land in adjuvant, neoadjuvant, metastatic and every space you can imagine in the next few years.
Question is do we combo single plus pan or single plus chemo, and what is the added agent (especially in CRC)?
@OncoAlert @TheGutOncLab @Onco_Nexus @Incyte
James Cleary retweeted
🔬Ivonescimab now represent a promising emerging therapeutic option - exciting progress for cholangiocarcinoma and biliary tract cancer patients @curecc
HARMONI-GI1 at the @myESMO #ESMO26 #Presidential of CisGem + #ivonescimab vs durvalumab in #firstline #BiliaryMalignancies
✅OS HR 0.75, mOS 12.1vs14.9
✅PFS HR 0.61, mPFS 6.8vs8.4
✅ORR 53.8vs32.5
🌐China only
BUT
😊This is a positive trial
🥳VEGF is back
#ESMOAmbassadors
James Cleary retweeted
🔥Presidential session at ESMO 2026 🔥
HARMONi-GI1 ph-3: Ivonescimab + CTx vs durvalumab + CTx as 1L for BTC
#ESMO26 #ESMOAmbassadors
👉ORR: 53.8 vs. 32.5 %
👉mPFS: 8.4 vs 5.8 mo
👉mOS: 14.9 vs. 12.1 mo
🧐 Very promising Chinese data, would be great to see data in a global population
@myESMO @ASCO
James Cleary retweeted
CLARITY- Gastric 01 (CG-01) Phase III AZD-0901 (Sone-Ve) in 2L+ met #Claudin 18.2 (+) in #Gastroesophageal #cancer vs. investigators choice (N=594)
Primary endpoints: PFS + OS
🔹OS: 10M vs. 5M (HR = 0.47) 👏
🔹12M OS: 38.1% vs. 18.1%, HR = 0.47 (3rd line)
🔹 12M 42.6% in 2nd line
🔹 ORR: 23.3% vs. 13.8%
🔹PFS: HR = 0.77 was NS in 2L+
🔹PFS: HR = 4.1 vs. 2.7M; HR = 0.56 in 3L+
🔹Need more data in the 2L setting; largest benefit seen in 3L+ setting
#ESMO2026 @OncoAlert #cancerresearch @AstraZeneca
James Cleary retweeted
Another win for olanzapine and for many patients
ascopubs.org/doi/abs/10.1200…
James Cleary retweeted
Encorafenib plus cetuximab beyond progression in combination with FOLFIRI in BRAF V600E mCRC progressing on EC: Results from the ECLYPse phase II trial
#ESMO26 #ESMOAmbassadors
👉 mPFS: 7.1
👉 mOS: NR
👉ORR 15%
🧐Interesting signal to continue EC, more translational data would be great
@myESMO @ASCO
James Cleary retweeted
#ESMO26 | IROCAS
I think we can finally put this debate to rest
In high-risk stage III colon cancer, intensifying adjuvant chemotherapy with mFOLFIRINOX failed to improve DFS over mFOLFOX6
We need to rethink our approach to treatment escalation in the adjuvant setting. Simply adding more conventional cytotoxic agents is not the answer.
James Cleary retweeted
HARMONi-GI1, presidential session at #ESMO26.
@UGrewalMD guessed .7 HR
I guessed .8 HR
We were equally right (.75 HR).
Phase 3, 1L advanced biliary tract cancer: ivonescimab (PD-1 x VEGF) + GemCis vs durvalumab + GemCis. 682 patients, median follow-up 14.3 mo.
OS 14.9 vs 12.1 mo, HR 0.75 (95% CI 0.61-0.92), p=0.0031
PFS 8.4 vs 5.8 mo, HR 0.61 (95% CI 0.51-0.72)
ORR 53.8% vs 32.5%
This was an appropriate comparator for 2026 and compelling data (although really did need every one of those patients to power).
Probable new first line once the full data comes out.
The bispecifics era is in full force.
@OncoAlert @TheGutOncLab @UGrewalMD @Onco_Nexus
James Cleary retweeted
FOLFIRI plus ramucirumab vs paclitaxel plus ramucirumab as 2L therapy for taxane-pretreated patients with mGEA–Final results of the phase III IKFs602/AIO RAMIRIS Study
#ESMO26 #ESMOAmbassadors
👉 ORR: 25 vs 23%
👉 mPFS: 5.5 vs 3.7 mo
👉 mOS: 8.7 vs 7.5 mo
🧐neg. study, but FOLFIRI + Ram appears reasonable option
@myESMO @ASCO
James Cleary retweeted
VS-7375: A KRAS G12D ON/OFF KRAS inhibitor. 🎯
Preclinical rationale for combinations with pan-RAS, EGFR, FAK or PRMT5 inhibitors.
Jonathan Pachter, PhD, Chief Scientific Officer @VerastemOncolog
RAS Initiative Symposium 2026, Frederick, Maryland, October 7-9, 2026
📎
verastem.com/wp-content/uplo…
James Cleary retweeted
Preliminary clinical results of QTX3034, an oral G12D-preferring KRAS inhibitor with cetuximab ± mFOLFOX6 in KRASG12D-mCRC
#ESMO26 #ESMOAmbassadors
👉ORR: 25% vs 50%, DCR: 75 vs 90%
👉 no new safety signals
🧐Supports the combination with CTx
@myESMO @ASCO
James Cleary retweeted
Long-term follow-up of Temab-A with Bev vs SOC in 3L+ CRC: Updated results of a ph 1
#ESMO26 #ESMOAmbassadors
👉 mPFS: 6.8 vs 4.2 mo
👉 mOS: 14.7 vs 10.2 mo
👉 manageable safety
🧐Promising, ph-3 ongoing
@myESMO @ASCO
James Cleary retweeted
Phase I study of BGB-B2033 (GPC3 x 4-1BB bispecific AB): Dose optimization and escalation update in advanced HCC
#ESMO26 #ESMOAmbassadors
👉ORR: 30%
👉manageable safety
🧐very promising agent, looking forward to see combination with ICI
@myESMO @ASCO
James Cleary retweeted
Paclitaxel +\-tovecimig: COMPANION-002 ph2/3
➡️prev treated #BTC wo actionable alterations
➡️ORR 17.1 v5.3%; DCR 62 v 37%
➡️mPFS 4.7 v 2.6mths - benefits seen at PFS2 noting crossover
➡️OS not sig but nb crossover
@myESMO #ESMO26 @OncoAlert
